CN105764495A - 用于管理疼痛的包含右旋美托咪啶经皮组合物的方法及组合物 - Google Patents

用于管理疼痛的包含右旋美托咪啶经皮组合物的方法及组合物 Download PDF

Info

Publication number
CN105764495A
CN105764495A CN201480064109.XA CN201480064109A CN105764495A CN 105764495 A CN105764495 A CN 105764495A CN 201480064109 A CN201480064109 A CN 201480064109A CN 105764495 A CN105764495 A CN 105764495A
Authority
CN
China
Prior art keywords
dexmedetomidine
subject
pain
delivery device
transdermal delivery
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480064109.XA
Other languages
English (en)
Chinese (zh)
Inventor
阿德查拉·蓬皮拉帕特
阿米特·杰恩
布雷特·伯纳
温建业
首藤十太郎
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teikoku Pharma USA Inc
Original Assignee
Teikoku Pharma USA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teikoku Pharma USA Inc filed Critical Teikoku Pharma USA Inc
Priority to CN201910851561.5A priority Critical patent/CN110604728A/zh
Publication of CN105764495A publication Critical patent/CN105764495A/zh
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/4174Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061Polyacrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN201480064109.XA 2013-10-07 2014-10-03 用于管理疼痛的包含右旋美托咪啶经皮组合物的方法及组合物 Pending CN105764495A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910851561.5A CN110604728A (zh) 2013-10-07 2014-10-03 用于管理疼痛的包含右旋美托咪啶经皮组合物的方法及组合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361887870P 2013-10-07 2013-10-07
US61/887,870 2013-10-07
PCT/US2014/059057 WO2015054062A2 (en) 2013-10-07 2014-10-03 Methods and compositions for managing pain comprising dexmedetomidine transdermal compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201910851561.5A Division CN110604728A (zh) 2013-10-07 2014-10-03 用于管理疼痛的包含右旋美托咪啶经皮组合物的方法及组合物

Publications (1)

Publication Number Publication Date
CN105764495A true CN105764495A (zh) 2016-07-13

Family

ID=52777129

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201480064109.XA Pending CN105764495A (zh) 2013-10-07 2014-10-03 用于管理疼痛的包含右旋美托咪啶经皮组合物的方法及组合物
CN201910851561.5A Pending CN110604728A (zh) 2013-10-07 2014-10-03 用于管理疼痛的包含右旋美托咪啶经皮组合物的方法及组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201910851561.5A Pending CN110604728A (zh) 2013-10-07 2014-10-03 用于管理疼痛的包含右旋美托咪啶经皮组合物的方法及组合物

Country Status (10)

Country Link
US (2) US20150098982A1 (https=)
EP (1) EP3054931B1 (https=)
JP (2) JP6188934B2 (https=)
KR (2) KR20180095733A (https=)
CN (2) CN105764495A (https=)
CA (1) CA2924188C (https=)
ES (1) ES2855103T3 (https=)
RU (1) RU2654702C2 (https=)
TW (1) TWI629061B (https=)
WO (1) WO2015054062A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110022865A (zh) * 2016-10-31 2019-07-16 帝国制药美国公司 使用右美托咪定经皮递送装置管理疼痛的方法

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101948779B1 (ko) 2013-10-07 2019-05-21 테이코쿠 팔마 유에스에이, 인코포레이티드 덱스메데토미딘 경피 전달 장치 및 이의 사용 방법
US20150098982A1 (en) * 2013-10-07 2015-04-09 Teikoku Pharma Usa, Inc. Methods and Compositions for Managing Pain Comprising Dexmedetomidine Transdermal Compositions
CA2924233C (en) 2013-10-07 2018-10-23 Teikoku Pharma Usa, Inc. Methods and compositions for treating attention deficit hyperactivity disorder, anxiety and insomnia using dexmedetomidine transdermal compositions
CA2924236C (en) 2013-10-07 2020-01-07 Teikoku Pharma Usa, Inc. Methods and compositions for transdermal delivery of a non-sedative amount of dexmedetomidine
IL267689B2 (en) 2016-12-31 2025-05-01 Bioxcel Therapeutics Inc Use of sublingual dexmedetomidine for the treatment of agitation
BR112020026672A2 (pt) 2018-06-27 2021-03-30 Bioxcel Therapeutics, Inc. Formulações de filme contendo dexmedetomidina e métodos para produzi-las
US12472158B2 (en) 2019-02-27 2025-11-18 Vanderbilt University Methods of treating trigeminal nerve pain
EP3962478A1 (en) 2019-05-01 2022-03-09 Clexio Biosciences Ltd. Methods of treating pruritus
US20220211672A1 (en) 2019-05-01 2022-07-07 Clexio Biosciences Ltd. Methods of treating pruritus
BR112022000992A2 (pt) 2019-07-19 2022-06-14 Arx Llc Regimes de tratamento de dexmedetomidina não sedantes
CN117582424A (zh) * 2022-08-17 2024-02-23 宜昌人福药业有限责任公司 右美托咪定经皮组合物、透皮贴剂及其制备方法和应用
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1035922C (zh) * 1989-08-18 1997-09-24 天鹅探究有限公司 经皮肤使用的右旋美托咪定系统的制备方法
US6071531A (en) * 1995-06-07 2000-06-06 Ortho-Mcneil Pharmaceutical, Inc. Transdermal patch and method for administering 17-deacetyl norgestimate alone or in combination with an estrogen
US20090258063A1 (en) * 2006-09-11 2009-10-15 Sekisui Chemical Co., Ltd. Transdermal patch
CN101835467A (zh) * 2008-04-18 2010-09-15 华沙整形外科股份有限公司 用于治疗疼痛和/或炎症的α-肾上腺素能受体激动剂
CN102753169A (zh) * 2010-01-08 2012-10-24 瑞克欧制药有限公司 外用透皮右美托咪啶组合物及其应用方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9111732D0 (en) * 1991-05-31 1991-07-24 Orion Yhtymae Oy The use of certain salts of medetomidine and its optically active enantiomers to regulate the rate of transdermal administration of the drugs
GB2290964A (en) * 1994-07-08 1996-01-17 Arto Olavi Urtti Transdermal drug delivery system
MXPA01003310A (es) * 1998-10-02 2003-05-15 3M Innovative Properties Co Sistema de suministro de farmaco originados en mucosa y aplicaciones animales.
US7635488B2 (en) * 2001-03-13 2009-12-22 Dbv Technologies Patches and uses thereof
KR100511492B1 (ko) * 2002-10-11 2005-08-31 주식회사 태평양 에페리손, 톨페리손 또는 그것들의 염을 포함하는경피흡수제제
TWI341735B (en) * 2003-07-31 2011-05-11 Hisamitsu Pharmaceutical Co Adhesive preparations
WO2005034998A2 (en) * 2003-09-12 2005-04-21 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
MX2007000480A (es) * 2004-07-15 2007-03-29 Japan Tobacco Inc Compuesto de benzamida fusionado e inhibidor de actividad de receptor de vainilloide 1.
US8383149B2 (en) * 2005-09-23 2013-02-26 Alza Corporation High enhancer-loading polyacrylate formulation for transdermal applications
US20070134310A1 (en) * 2005-09-23 2007-06-14 Nedberge Diane E Transdermal risperidone delivery system
EP2286814B1 (en) * 2008-05-15 2013-10-16 Hisamitsu Pharmaceutical Co., Inc. Transdermal preparation containing palonosetron
WO2010014076A1 (en) * 2008-07-28 2010-02-04 EndogenX, Inc. Methods to treat pain using an alpha-2 adrenergic agonist and an endothelin antagonist
US9308203B2 (en) * 2008-10-01 2016-04-12 Taiwan Biotech Co., Ltd. Pressure sensitive adhesive matrix device or system for the treatment or prevention of onychomycosis or tinea pedis
US8563031B2 (en) * 2010-05-27 2013-10-22 Absize, Inc. Piroxicam-containing matrix patches and methods for the topical treatment of acute and chronic pain and inflammation therewith
AU2011331511C1 (en) * 2010-11-17 2018-01-18 Hexal Ag Transdermal therapeutic system comprising buprenorphine
US20130096170A1 (en) * 2011-10-14 2013-04-18 Hospira, Inc. Methods of treating pediatric patients using dexmedetomidine
US20150098982A1 (en) * 2013-10-07 2015-04-09 Teikoku Pharma Usa, Inc. Methods and Compositions for Managing Pain Comprising Dexmedetomidine Transdermal Compositions

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1035922C (zh) * 1989-08-18 1997-09-24 天鹅探究有限公司 经皮肤使用的右旋美托咪定系统的制备方法
US6071531A (en) * 1995-06-07 2000-06-06 Ortho-Mcneil Pharmaceutical, Inc. Transdermal patch and method for administering 17-deacetyl norgestimate alone or in combination with an estrogen
US20090258063A1 (en) * 2006-09-11 2009-10-15 Sekisui Chemical Co., Ltd. Transdermal patch
CN101835467A (zh) * 2008-04-18 2010-09-15 华沙整形外科股份有限公司 用于治疗疼痛和/或炎症的α-肾上腺素能受体激动剂
CN102753169A (zh) * 2010-01-08 2012-10-24 瑞克欧制药有限公司 外用透皮右美托咪啶组合物及其应用方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110022865A (zh) * 2016-10-31 2019-07-16 帝国制药美国公司 使用右美托咪定经皮递送装置管理疼痛的方法

Also Published As

Publication number Publication date
US20240245652A1 (en) 2024-07-25
JP2018008984A (ja) 2018-01-18
JP6522062B2 (ja) 2019-05-29
TWI629061B (zh) 2018-07-11
JP2016532645A (ja) 2016-10-20
EP3054931A2 (en) 2016-08-17
CN110604728A (zh) 2019-12-24
US20150098982A1 (en) 2015-04-09
WO2015054062A2 (en) 2015-04-16
TW201524506A (zh) 2015-07-01
CA2924188C (en) 2018-12-18
JP6188934B2 (ja) 2017-08-30
BR112016007327A2 (pt) 2017-08-01
ES2855103T3 (es) 2021-09-23
KR101891186B1 (ko) 2018-08-24
EP3054931B1 (en) 2020-12-23
RU2654702C2 (ru) 2018-05-22
KR20180095733A (ko) 2018-08-27
EP3054931A4 (en) 2017-04-05
RU2016109631A (ru) 2017-11-15
KR20160062159A (ko) 2016-06-01
CA2924188A1 (en) 2015-04-16

Similar Documents

Publication Publication Date Title
US20240245652A1 (en) Methods and compositions for managing pain comprising dexmedetomidine transdermal compositions
CA2924231C (en) Dexmedetomidine transdermal delivery devices and methods for using the same
CN106456561B (zh) 使用右旋美托咪啶经皮组合物治疗注意力缺陷多动症、焦虑症和失眠症的方法和组合物
CN105764496B (zh) 用于经皮递送非镇静量的右旋美托咪啶的方法和组合物
HK40018815A (en) Methods and compositions for managing pain comprising dexmedetomidine transdermal compositions
HK40018790A (en) Dexmedetomidine transdermal delivery devices and methods for using the same
JP6208859B6 (ja) デクスメデトミジン経皮送達デバイス及びその使用法
BR112016007327B1 (pt) Uso de dispositivo de distribuição transdérmica para controlar dor

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20160713

RJ01 Rejection of invention patent application after publication